Stock AnalizCardinal Health Inc. CAH
Other Pharmaceuticals · data as of November 13, 2026
Cardinal Health Inc. (CAH) is a healthcare company listed in the US with a market value of about $65.0B. In the twelve months to September 30, 2026 it had revenue of $257.8B and net income of $1.8B, a net margin of 0.7%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is shareholder returns (5/5); the weakest is value (3/5).
Key numbers: a P/E of 36.4, a price to free cash flow of 13.3, 5-year revenue growth of 9% a year, a 5-year average ROIC of 22%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 16% above the current price.
Score: 3.4 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- ROE above 15%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $257.8B | $254.2B | $222.6B | $226.8B | $205.0B | $181.3B | $162.5B | $152.9B | $145.5B | $136.8B | $130.0B |
| Net income | $1.8B | $1.7B | $1.6B | $852M | $330M | -$938M | $611M | -$3.7B | $1.4B | $256M | $1.3B |
| Free cash flow | $4.9B | $4.5B | $1.9B | $3.3B | $2.4B | $2.8B | $2.0B | $1.6B | $2.4B | $2.4B | $797M |
| EPS (diluted) | $7.72 | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 |
| Net margin | 0.7% | 0.7% | 0.7% | 0.4% | 0.2% | -0.5% | 0.4% | -2.4% | 0.9% | 0.2% | 1.0% |
| ROIC | — | 29.0% | 25.9% | 36.9% | 26.8% | -9.4% | 4.4% | -44.5% | 11.2% | 0.7% | 8.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $294.87, 5% above the current price; targets range from $260.00 to $330.00; the consensus rating is “Buy”; expected EPS is $13.00 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is Cardinal Health’s P/E ratio?
About 36.4, based on the last twelve months of diluted earnings per share (forward P/E about 20.6).
Is Cardinal Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 16% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cardinal Health pay a dividend?
Yes. The dividend yield is about 0.74%, and it has paid dividends for 10 years in our data.
Is Cardinal Health a good stock to buy?
We do not give buy or sell advice. Cardinal Health scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.